Skip to content

Construction and Clinical Application of a Digital Lipid Management System Based on Large Language Models

Construction and Clinical Application of a Digital Lipid Management System Based on Large Language Models

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125714
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerotic cardiovascular disease

Interventions

Experimental group:AI + Intelligent Management
Control group:Routine Management

Sponsors

Nanfang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the informed consent form; 2. Age >= 18; 3. LDL-C >= 70 mg/dl; 4. Meet the diagnostic criteria for atherosclerotic cardiovascular disease (clinical manifestations or imaging evidence); 5. 18.5 <= BMI <= 40 kg/m^2.

Exclusion criteria

Exclusion criteria: 1.Those who had ketoacidosis or hyperosmolar state within the previous 6 months and required hospitalization for treatment, or whose HbA1c was >= 8% before the screening; 2.Those who had experienced myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, peripheral artery disease, or transient ischemic attack within the previous 3 months; 3.Those with left ventricular ejection fraction < 30%; 4.Those with severe hematological diseases; 5.Those with severe renal dysfunction; 6.Those with severe diseases and an expected lifespan of less than 1 year; 7.Those who participated in other drug clinical trials in the past 1 year; 8.As determined by the investigator, those who are not suitable to participate in this study;

Design outcomes

Primary

MeasureTime frame
Percentage change in LDL-C levels from baseline at 12 months;

Secondary

MeasureTime frame
Clinical endpoints (cardiovascular mortality, myocardial infarction, revascularization, rehospitalization rate, stroke, and other MACE incidence);Alternative endpoints (changes in electrocardiogram, changes in UCG indicators, 6-minute walk distance, quality of life scores, changes in physical indicators, changes in laboratory indicators, adherence to guideline-recommended medications);Health-related quality of life (assessed using the SF-36 Health Survey);

Countries

China

Contacts

Public ContactHua Zheng

Nanfang Hospital, Southern Medical University

gzhzmd@126.com+86 20 6278 7094

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026